OBJECTIVES: Tuberculosis (TB) is one of the major communicable diseases around the world and an estimated 9 million people were diagnosed based on the report from World Health Organization (WHO). With 12,338 new cases and 626 TB-related deaths in 2012, TB remains the highest incidence and mortality rate among all airborne contagious diseases in Taiwan. Conventional methods, sputum acid-fast bacilli (AFB) smear microscopy and culture of TB bacteria on liquid or solid media, can be inaccurate and time-consuming. The study aimed to determine the accuracy of the GeneXpert MTB/RIF system, a commercially available nucleic acid amplification technology, in diagnosing TB. METHODS: A total of 1641 samples were collected in a medical center from January 2016 to December 2017. Lowenstein-Jensen (L-J) solid medium, Mycobacterium Growth Indicator Tube (MGIT), and GeneXpert MTB/RIF assay were performed to identify Mycobacteria. Additionally, culture based conventional drug susceptibility test (DST) was administered to measure the efficacy of this molecular method. RESULTS: The sensitivity and specificity of the GeneXpert MTB/RIF were90.1% (128/142) and 98.1% (1471/1499) respectively. The negative predictive value (NPV) was 99.1% (1471/1485) and positive predictive value (PPV) was 82.1% (128/156). The MTB/RIF assay also detected 1 rifampicin resistant specimen from the 1641 cases, and the results were confirmed by drug susceptibility testing. Besides, the turnaround time for TB confirmation test decreased from 2-3 weeks to 2-3 hours in this microbiology laboratory. CONCLUSIONS: In conclusion, the GeneXpert MTB/RIF system exhibits high sensitivity and specificity for detecting tuberculosis and has the potential to apply to other human infectious pathogens. The study shows that the laboratory requires an efficient and accurate tool for identifying communicable disease. Timely confirmation of communicable diseases can lead to earlier treatment for the suspected individual, decrease the chance of transmission in the clinical settings, and provide more effective public health interventions.
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PMD30 1 YEAR HEALTH-RELATED QUALITY-OF-LIFE OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH END-STAGE RENAL FAILURE
Yan BP 1 , Chan LL 1 , Lai WH 1 , To OT 1 , Reid C 2 , Lee VW 1 1 The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2 Monash University, Melbourne, Australia OBJECTIVES: End-stage renal failure (ESRF) is an important predictor of adverse clinical outcomes after percutaneous coronary intervention (PCI). There is a paucity of healthrelated quality-of-life (HRQoL) data regarding association between ESRF and health status after PCI. We aim to evaluate the impact of ESRF on HRQoL after PCI. METHODS: We retrospectively analyzed 2,938 consecutive patients who underwent PCI between Jan 2004 and December 2013 at a tertiary academic institution in Hong Kong. HRQoL was assessed with EuroQoL-5D (EQ-5D) health survey and visual analog scale (VAS). Baseline characteristics and 1-year clinical outcomes including death, myocardial infarction (MI), target-vessel revascularization (TVR) and composite major adverse cardiac events (MACE) were evaluated. Minimally important benefit (MIB, defined as greater than half a standard deviation improvement of baseline VAS score) in HRQoL at 1 year was compared between patient with and without ESRF. RESULTS: Of 2938 PCI, 4.4% (n= 129) of patients had ESRF (70.5% male with mean age of 64.8 years). ESRF patients had significantly more co-morbidities including diabetes, hypertension, peripheral arterial disease, stroke, heart failure, acute coronary syndrome and in-stent restenosis compared to non-ESRF (all p< 0.05). ESRF patients had significantly higher rates of 1-year all-cause mortality (21.7% vs 3.3%, p< 0.01), TVR (3.9% vs 1.4%, p= 0.02) and MACE (25.6% vs 5.8%, p< 0.01) compared to non-ESRF patients respectively. Mean VAS scores at baseline (53.6±21.9 vs. 51.6±22.7) and 1-year (71.7±14.7 vs. 68.7±16.1, both P= NS) were similar between two groups. Proportion of ESRF patients (55.7%) who experienced MIB at 1-year was comparable with non-ESRF patients (54.9%, p= NS). Consistent results were observed after propensity score matching. CONCLUSIONS: ESRF patients experienced similar improvement in quality-of-life compared to patients without ESRF who underwent PCI. Our findings suggested that ESRF status per se should not deter against revascularization because of potential benefits in quality-of-life.
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PMD31 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY WITH COMPUTERISED TOMOGRAPHY FOR ONCOLOGICAL INDICATIONS: A PRAGMATIC APPROACH TO GUIDE SUBSIDY DECISIONS
Chng KR, Ju H, Soon SS, Ng KH Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore, Singapore OBJECTIVES: In Singapore, the use of fluorodeoxyglucose positron emission tomography with computerised tomography (FDG-PET-CT) in oncology has been steadily increasing over recent years. This research aims to assess the effectiveness of FDG-PET-CT for different oncological indications to guide subsidy decisions. METHODS: Due to the large volume of evidence on PET-CT use, a pragmatic approach was taken to balance between the resources required and the robustness of the review. Instead of reviewing primary evidence, recommendations or top-line summaries from relevant reports and guidelines from other health technology assessment (HTA) agencies were collated. Relevant information was independently extracted and interpreted by two reviewers. Extracted information was categorised based on different functions of PET-CT (i.e. diagnosis, staging, and monitoring) in oncology. To ensure consistency in reaching recommendations for PET-CT use, decision rules were developed and applied to integrate conclusions across different agencies. Any differences in interpretations were resolved through discussion. RESULTS: A total of 21 HTA reports and 7 guidelines were reviewed. The evidence revealed that the effectiveness of PET-CT varied across oncological indications and among different prospective study (conducted 1/7/2017-30/9/2017) included time-in-motion direct observations of 15 TKAs, supplemented by literature and 21 interviews with hospital staff. Time-Driven Activity Based Costing (TDABC) methodology was used to identify who performed each step, its duration, and associated costs. Personnel costs for each phase of instrument management were measured based on job category labour rates. RESULTS: To support a 117 minute surgery, instruments were processed over a 6 day span behind the scenes, taking a total of 1,129 minutes from scheduling each TKA to return of instruments to storage. The hospital required at least 6 types of staff to manage re-usable surgical instruments: doctors, OT nurses, scrub nurses, central supply nurse assistants, medical office assistants, and medical engineers. This labour cost amounted to ¥65,027, which was nearly on par with mobilizing the entire surgical team for the TKA procedure (¥80,792). Hospital cost was split across pre-surgery (18%), surgery (73%), and post-surgery (9%). CONCLUSIONS: The surgical instruments management process and their influence on the overall cost of the TKA procedure has been brought to light for the first time in Japan. This exploratory study has identified important opportunities for the hospital to improve efficiency, especially for this relatively complex process requiring a high burden of support activities from skilled hospital staff. Lee J, Ahn J Ewha Womans University, Seoul, Korea, Republic of (South) OBJECTIVES: There is no study published on HRQOL of Korean pregnant women which is needed to evaluate innovative technologies such as non-invasive prenatal testing (NIPT) in Korea. The objective of this study is to document health utility of Korean pregnant women before and after prenatal tests. METHODS: Data for this study came from NECA-NHCR research on prenatal testing. During the period of May 2016 to February 2018, pregnant women who received a prenatal test at twelve clinical sites in Korea were solicited for EQ-5D-5L based health utility before and after prenatal test. The after-test utility measurement was performed right after informing the negative test results. For those who received multiple tests and positive results were excluded. A total of 210 pregnant women participated. Health utility was calculated using EQ-5D-5L Korean tariff and EQ-VAS. All analyses were performed by SPSS Statistics version21.0. RESULTS: The mean gestational age in before-test and after-test measurements were 12.29(±2.84) and 22(±7.6) weeks, respectively. The mean gestational age for after-test measurement was 23(±7.4) weeks for maternal serum test, 19.2(±5.3) weeks for NIPT and 27.1(±8.8) weeks for invasive test. NIPT showed significantly early testing than two other tests(p< 0.05). Overall, the mean scores of EQ-5D-5L were 0.919(±0.088) before-test and 0.901(±0.101) after-test. The mean EQ-5D-5L was 0.896(±0.104) after maternal serum test, 0.913(±0.0938) after NIPT, and 0.886(±0.108) after invasive prenatal test. The health utility of all participants measured by EQ-VAS were 0.798(±0.124) before the test and 0.822(±0.108) after the test. The mean EQ-VAS utility was 0.820(±0.109) after maternal serum test, 0.836(±0.104) after NIPT, and 0.780(±0.57) after invasive test. CONCLUSIONS: This study reported health utilities of pregnant women before and after various prenatal tests. These results and future work on gestational week adjusted health utility data can significantly help building economic evaluation model on prevailing prenatal testing including NIPT in Korea.
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PMD27
HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PREGNANT WOMEN IN KOREA: A COMPARISON BEFORE AND AFTER PRENATAL TEST
PMD28 CONSUMER WILLINGNESS-TO-PAY AND PREFERENCE FOR SKIN CANCER SCREENING SERVICES IN AUSTRALIA
Snoswell CL 1 , Whitty JA 2 , Caffery LJ 1 , Loescher L 3 , Gillespie N 1 , Vagenas D 4 , Soyer HP 1 , Janda M 1 1 The University of Queensland, Brisbane, Australia, 2 University of East Anglia, Norwich, Australia, 3 University of Arizona, Tucson, AZ, Australia, 4 Queensland University of Technology, Brisbane, Australia OBJECTIVES: To determine consumer preferences and willingness-to-pay for skin cancer screening services in Australia. METHODS: During 2016-2017, 113 participants in a randomised controlled trial comparing self-skin examination and mobile teledermoscopy completed a discrete choice experiment (DCE) question set about skin cancer screening services. The DCE question set was comprised of 24 questions, divided into in two blocks. For each question, respondents were asked to make discrete choices between mutually exclusive skin cancer screening services options described by 7 attributes with 2-3 levels. Each question also had 2 opt-out choices; 'skin self-examination' and 'do nothing'. This DCE was designed using the principle of d-efficiency and analysed using a mixed logit model. All variables except cost were effects coded. The model was used to estimate preferences for skin cancer screening services, and measures of interest such as marginal willingness to pay, and uptake of new services. RESULTS: Diagnostic accuracy was the most important factor for consumers when choosing a skin cancer screening option, closely followed by the number of benign lesions removed to find one melanoma. Consumers preferred having a professional involved in their skin cancer screening, rather than performing a self-examination. Additionally, the model indicated a preference for services that offered shorter waiting time for diagnosis, and minimal time away from usual activities. When selecting a mobile teledermoscopy screening service, consumers were willing to pay an extra AU$43 to have the images reviewed by a dermatologist instead of a general practitioner. Consumers were also willing to pay AU$64 to reduce this time away from usual activities from 3-4 hours down to 1-2 hours. CONCLUSIONS: Skin cancer screening services which were delivered by health professionals and offered optimal diagnostic accuracy were preferred by consumers. They were willing to pay for their preferred skin cancer screening method, especially if a dermatologist was involved.
